The global non-small cell lung cancer market is expected to gain significant demand during the forecast period. Lung cancer is differentiated into two types as non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Lung cancer is the uncontrolled growth of cells in the lung tissues. The majority of lung cancers are NSCLC. Common symptoms are chest pain, wheezing, coughing up blood, hoarseness, weight loss, recurring bronchitis, loss of appetite, fatigue, shortness of breath, bone pain, swallowing difficulty, and numbness of limbs. Increasing incidences of lung cancer due to smoking, air pollution (asbestos, cadmium, and radon), HIV infection, and population growth are few of the growth drivers of the NSCLC market.
Non-small cell lung cancer market is segmented into two types on the basis of histology and treatment. The histological segment is further subdivided into three types as SCC or squamous cell carcinoma, large cell carcinoma, and adenocarcinoma. SCC is found near bronchus in the middle of the lungs in the squamous cells. Large cell carcinoma or undifferentiated type occurs in any part of the lung, fastest-growing and is difficult to treat. Adenocarcinoma is slowest growing compared to the other two types and is found in the cells responsible for mucous secretion in outer lung parts. The second type of treatment is further sub-segmented into three types as surgery, chemotherapy, and radiation. Surgery is used for the first two phases of NSCLC includes pneumonectomy(entire lung removal), lobectomy (section removal of the lung), and wedge resection(exclusion of part of the lobe). Chemotherapy is prescribed for an appreciable number of lung cancer patients. The ASCO or American Society for Clinical Oncology guidelines suggest the use of platinum combination therapy for first-line NSCLC treatment. Carboplatin and cisplatin are other chemotherapeutic drugs used. Radiation, the third type of treatment is used in stage one and two of NSCLC when surgical procedures are not possible. Radiation therapy is complimented with beta-blockers for disease-free patient survival. The diagnosis of NSCLC is a two-stage process of testing and staging. Testing is done with the help of radiography, X-ray, bronchoscopy, or CT biopsy. Staging is done after testing and the results are reported in tumor node metastasis or TNM system.
The geographic segmentation of the non-small cell lung cancer market is into four regions such as Europe, North America, Asia Pacific, and RoW. North America is expected to have the largest market share followed by Europe in the forecasted period. Owing to increased smoking habits in developing countries Asia Pacific region can also be predicted to be a significant contributor to the NSCLC market. The key players in the NSCLC market are Tarceva, Avastin, Gemzar, Alimta, Taxotere, AstraZeneca, Roche, and Merck KGa
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
ESOMAR certified & member
Leading SME award by D&B
"The quality of research they have done for us has been excellent."
Multiple therapeutic regimens are being followed across the globe in attempts to come up with a reliable treatment for Covid-19. One line of treatment includes the use of hydroxychloroquine, while a second treatment line focuses to use antiviral drugs used in the disease management of HIV. Both these approaches have surged demand from advanced antivirals and antimalarial drugs. This impacts the drug manufacturers as an off label indication for these drug classes has to be worked upon. At the moment, the WHO has not prescribed any of these approaches, neither they have commented if one is better than the other. The report will account for Covid19 as a key market contributor.